Skip to main content

Articles

In-Depth Drug Profile
Exa-cel and Lovo-cel Provide Potential Functional Cure for Patients with SCD or TDT
Jerm Day-Storms, PhD, MWC
Read More
FDA Pipeline
Upcoming FDA Actions, January Through March 2024
Read More
FDA Approvals
Directory of FDA Approvals, August Through December 2023
Read More
FDA Approvals
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Read More
FDA Approvals
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Read More
FDA Approvals
Ogsiveo First Treatment FDA Approved for Desmoid Tumors
Read More
FDA Approvals, Gastroenterology
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Read More
FDA Approvals
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Read More
FDA Approvals
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Read More
FDA Approvals
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
Read More
Page 6 of 244
Results 51 - 60 of 2440